Trial of Rifaximin in the Treatment of Tropical Enteropathy
NCT ID: NCT00858988
Last Updated: 2019-11-12
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
147 participants
INTERVENTIONAL
2007-09-30
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combined Package of Interventions for Environmental Enteropathy
NCT02253095
Study of Nitazoxanide in the Treatment of Amebiasis in Children
NCT00366730
Effectiveness of Micronutrient Supplementation and Fish Oil + Micronutrient Supplementation in the Treatment of Environmental Enteropathy
NCT01593033
Effectiveness of High-dose Zinc Therapy and Albendazole in the Treatment of Environmental Enteropathy
NCT01440608
Effectiveness of Oral Antibiotics in the Treatment of Severe Acute Malnutrition
NCT01000298
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rifaximin
Rifaximin
100mg of rifaxin for 7 consecutive days, twice daily
Placebo
Placebo
twice daily for 7 consecutive days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rifaximin
100mg of rifaxin for 7 consecutive days, twice daily
Placebo
twice daily for 7 consecutive days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* acutely ill
* chronic disease
3 Years
5 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Baylor College of Medicine
OTHER
Kamuzu University of Health Sciences
OTHER
United States Department of Agriculture (USDA)
FED
Washington University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark J Manary
Role: PRINCIPAL_INVESTIGATOR
Washington University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Limela, , Malawi
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MJM-rifaximin
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.